Indeed, IL-4 confers protection to experimental colitis in DSS-sensitive C57BL/6 mice [30] and further support for this notion can be found in the abject failure of Brodalumab (an IL17-receptor neutralizing antibody) in Crohn's disease and the observation that this antibody increased mucosal inflammation. Here, IL4 is linked to colitis.